Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema
AIM:To evaluate the effects and safety of intravitreal injection of Ranibizumab on noninfectious uveitic macular edema(UME). <p>METHODS: This was an open and prospective study without control trial. Seventeen eyes from 17 patients with UME diagnosed by fundus fluorescein angiography(FFA)and op...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2018-09-01
|
| Series: | Guoji Yanke Zazhi |
| Subjects: | |
| Online Access: | http://ies.ijo.cn/cn_publish/2018/9/201809033.pdf |
| _version_ | 1818561149116874752 |
|---|---|
| author | Hong-Bin Xie Mei-Na Yang Xiao-Ping Zhou Jun Zhao Hong-Wei Deng Qing-Shan Chen |
| author_facet | Hong-Bin Xie Mei-Na Yang Xiao-Ping Zhou Jun Zhao Hong-Wei Deng Qing-Shan Chen |
| author_sort | Hong-Bin Xie |
| collection | DOAJ |
| description | AIM:To evaluate the effects and safety of intravitreal injection of Ranibizumab on noninfectious uveitic macular edema(UME). <p>METHODS: This was an open and prospective study without control trial. Seventeen eyes from 17 patients with UME diagnosed by fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled in this study. Before the injection, best-corrected visual acuity(BCVA)of early treatment of diabetic retinopathy study(ETDRS)and central macular thickness(CMT)measured by OCT were examined. All affected eyes were treated with intravitreal ranibizumab 0.05mL(0.5mg). The BCVA, CMT and intraocular pressure(IOP)were compared with baseline at 2, 4, 8 and 12wk after treatment. Related complications were recorded. <p>RESULTS: The median BCVA before treatment was 57(P<sub>25</sub> and P<sub>75</sub> were 52.5 and 64.5, respectively). The median CMT was 524μm(P<sub>25</sub> and P<sub>75</sub> were 365.5 and 571, respectively). At 2, 4, 8, and 12wk after injection, the median BCVA of the affected eyes was 76(P<sub>25</sub> and P<sub>75</sub> were 71 and 80, respectively), 81(P<sub>25</sub> and P<sub>75</sub> were 78.5 and 83, respectively), 82(P<sub>25</sub> and P<sub>75</sub> were 68.5 and 84, respectively), and 82(P<sub>25</sub> and P<sub>75</sub> are 78.5 and 83, respectively). The Friedman <i>M</i> test showed that there were differences in the BCVA in the four groups at different follow-up times, that was, BCVA after injection was higher than before injection(<i>χ</i><sup>2</sup>=47.58, <i>P</i><0.01). At 2, 4, 8, and 12wk after injection, the median CMT was 307μm(P<sub>25</sub> and P<sub>75</sub> were 249.5 and 374.5, respectively),231μm(P<sub>25</sub> and P<sub>75</sub> were 212.5 and 267), 219μm(P<sub>25</sub> and P<sub>75</sub> were 210.5 and 365.5,respectively), and 217μm(P<sub>25</sub> and P<sub>75</sub> were 201.5 and 366.5,respectively). The Friedman <i>M</i> test showed that there was difference in the CMT in the four groups at different follow-up times(<i>χ</i><sup>2</sup>=40.33, <i>P</i><0.01), that was, CMT after injection was lower than before injection. At the 12wk after injection, increased CMT and decreased BCVA were found in 35% of study eyes(6/17)that had uncontrolled intraocular inflammation, and all these patients needed to increase prednisone again. No adverse events were found during the follow-up duration.<p>CONCLUSION: Intravitreal ranibizumab is a safe and effective approach for noninfectious uveitic macular edema in the short term, which can significantly improve visual acuity and reduce CMT in patients refractory to or intolerant of standard corticosteroid/ immunomodulatory therapy. |
| first_indexed | 2024-12-14T00:47:12Z |
| format | Article |
| id | doaj.art-bcf81707fa7f4647b9a9429db825564f |
| institution | Directory Open Access Journal |
| issn | 1672-5123 1672-5123 |
| language | English |
| last_indexed | 2024-12-14T00:47:12Z |
| publishDate | 2018-09-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | Guoji Yanke Zazhi |
| spelling | doaj.art-bcf81707fa7f4647b9a9429db825564f2022-12-21T23:24:04ZengPress of International Journal of Ophthalmology (IJO PRESS)Guoji Yanke Zazhi1672-51231672-51232018-09-011891699170210.3980/j.issn.1672-5123.2018.9.33Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edemaHong-Bin Xie0Mei-Na Yang1Xiao-Ping Zhou2Jun Zhao3Hong-Wei Deng4Qing-Shan Chen5Shenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaShenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaShenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaShenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaShenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaShenzhen Eye Hospital; Affiliated Shenzhen Eye Hospital of Jinan University; Joint College of Optometry of Shenzhen University, Shenzhen 518020, Guangdong Province, ChinaAIM:To evaluate the effects and safety of intravitreal injection of Ranibizumab on noninfectious uveitic macular edema(UME). <p>METHODS: This was an open and prospective study without control trial. Seventeen eyes from 17 patients with UME diagnosed by fundus fluorescein angiography(FFA)and optical coherence tomography(OCT)were enrolled in this study. Before the injection, best-corrected visual acuity(BCVA)of early treatment of diabetic retinopathy study(ETDRS)and central macular thickness(CMT)measured by OCT were examined. All affected eyes were treated with intravitreal ranibizumab 0.05mL(0.5mg). The BCVA, CMT and intraocular pressure(IOP)were compared with baseline at 2, 4, 8 and 12wk after treatment. Related complications were recorded. <p>RESULTS: The median BCVA before treatment was 57(P<sub>25</sub> and P<sub>75</sub> were 52.5 and 64.5, respectively). The median CMT was 524μm(P<sub>25</sub> and P<sub>75</sub> were 365.5 and 571, respectively). At 2, 4, 8, and 12wk after injection, the median BCVA of the affected eyes was 76(P<sub>25</sub> and P<sub>75</sub> were 71 and 80, respectively), 81(P<sub>25</sub> and P<sub>75</sub> were 78.5 and 83, respectively), 82(P<sub>25</sub> and P<sub>75</sub> were 68.5 and 84, respectively), and 82(P<sub>25</sub> and P<sub>75</sub> are 78.5 and 83, respectively). The Friedman <i>M</i> test showed that there were differences in the BCVA in the four groups at different follow-up times, that was, BCVA after injection was higher than before injection(<i>χ</i><sup>2</sup>=47.58, <i>P</i><0.01). At 2, 4, 8, and 12wk after injection, the median CMT was 307μm(P<sub>25</sub> and P<sub>75</sub> were 249.5 and 374.5, respectively),231μm(P<sub>25</sub> and P<sub>75</sub> were 212.5 and 267), 219μm(P<sub>25</sub> and P<sub>75</sub> were 210.5 and 365.5,respectively), and 217μm(P<sub>25</sub> and P<sub>75</sub> were 201.5 and 366.5,respectively). The Friedman <i>M</i> test showed that there was difference in the CMT in the four groups at different follow-up times(<i>χ</i><sup>2</sup>=40.33, <i>P</i><0.01), that was, CMT after injection was lower than before injection. At the 12wk after injection, increased CMT and decreased BCVA were found in 35% of study eyes(6/17)that had uncontrolled intraocular inflammation, and all these patients needed to increase prednisone again. No adverse events were found during the follow-up duration.<p>CONCLUSION: Intravitreal ranibizumab is a safe and effective approach for noninfectious uveitic macular edema in the short term, which can significantly improve visual acuity and reduce CMT in patients refractory to or intolerant of standard corticosteroid/ immunomodulatory therapy.http://ies.ijo.cn/cn_publish/2018/9/201809033.pdfuveitismacular edemadrug therapyvascular endothelial growth factorranibizumabranibizumab |
| spellingShingle | Hong-Bin Xie Mei-Na Yang Xiao-Ping Zhou Jun Zhao Hong-Wei Deng Qing-Shan Chen Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema Guoji Yanke Zazhi uveitis macular edema drug therapy vascular endothelial growth factor ranibizumab ranibizumab |
| title | Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema |
| title_full | Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema |
| title_fullStr | Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema |
| title_full_unstemmed | Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema |
| title_short | Intravitreal injection of Ranibizumab treating noninfectious uveitic macular edema |
| title_sort | intravitreal injection of ranibizumab treating noninfectious uveitic macular edema |
| topic | uveitis macular edema drug therapy vascular endothelial growth factor ranibizumab ranibizumab |
| url | http://ies.ijo.cn/cn_publish/2018/9/201809033.pdf |
| work_keys_str_mv | AT hongbinxie intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema AT meinayang intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema AT xiaopingzhou intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema AT junzhao intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema AT hongweideng intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema AT qingshanchen intravitrealinjectionofranibizumabtreatingnoninfectiousuveiticmacularedema |